The MonarchE trial: improving the clinical outcome in HR<sup>+</sup>/HER2<sup>−</sup> early breast cancer: recent results and next steps

Bertucci, François; Finetti, Pascal; Mamessier, Émilie; Nonneville, Alexandre de

doi:10.1002/cac2.12466

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, several agents have been developed for the treatment of hormone receptor-positive breast cancer, especially targeted agents, such as CDK4/6 inhibitors [39,40], PIK3CA inhibitors [41], ESR1 inhibitors [42] and PIK3CA/AKT/PTEN inhibitors [43]. These drugs were selected for treatment by examining DNA mutations.…”

Section: Discussionmentioning

confidence: 99%

Breast cancer in Adolescent & Young Adult (AYA) has a specific biology and poor patient outcome compared to older patients

Oshi,

Yamada,

Gandhi

et al. 2024

Preprint

View full text Add to dashboard Cite

Background We aimed to clarify the features of adolescents and young adults (AYA: younger than 40yo) breast cancer (BC) compared with other age groups in ER-positive/HER2-negative BC, given the effects of age-related hormonal status. Methods The cohorts analyzed were divided into: AYA (15-39yo), Perimenopausal (40-54yo), Menopausal (55-64yo), and Old (65 + yo). Clinicopathological and biological features were analyzed using gene set variation analysis and the xCell algorithm using transcriptome profiles from large public databases of ER-positive/HER2-negative BC (METABRIC; n = 1,353, SCAN-B; n = 2,381). Results Tumors were larger and more advanced among the AYA and Old age groups than among the other groups. Pathological lymph node positivity and Nottingham grade 3 were higher among AYA. AYA was significantly associated with triple-negative BC and higher HER2-positivity. AYA had poorer disease-specific and overall survival particularly compared to perimenopausal group. In the ER-positive/HER2-negative subtype, estrogen response late signaling decreased with age. AYA was associated with significantly higher BRCAness and DNA repair than the other groups. AYA significantly enriched cell proliferation-related and pro-cancerous gene sets (MTORC1, unfolded protein response, and PI3K/AKT/MTOR signaling) when compared to the others. Interestingly, these features have also been observed in small tumors. Infiltration of CD8+, regulatory, and helper type 2 T cells, and M1 macrophages was higher, while M2 macrophages were lower in AYA. Finally, ER-positive/HER2-negative BC in AYA patients has different features of gene mutations compared to other age groups. Conclusions ER-positive/HER2-negative BC in AYA was highly proliferative with high immune cell infiltration compared to other generations.

show abstract

Section: Discussionmentioning

confidence: 99%

Breast cancer in Adolescent & Young Adult (AYA) has a specific biology and poor patient outcome compared to older patients

Oshi,

Yamada,

Gandhi

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Likewise, CD4/6 inhibitors have recently proven to be helpful in adjuvant treatment in the case of patients with high-risk HR+ BC, in studies like monarchE [68] and NATAL-LIE [69]. Therefore, questions arise as to whether this strategy will develop mutations that could restrict or favor the use of these or CD4/5 and PI3K inhibitors in the event of relapse or progression.…”

Section: Discussionmentioning

confidence: 99%

Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis

Martínez-Nava,

Urbina-Jara,

Lira-Albarrán

et al. 2024

Diagnostics

View full text Add to dashboard Cite

(1) Background: Somatic mutations may be connected to the exposome, potentially playing a role in breast cancer’s development and clinical outcomes. There needs to be information regarding Latin American women specifically, as they are underrepresented in clinical trials and have limited access to somatic analysis in their countries. This study aims to systematically investigate somatic mutations in breast cancer patients from Latin America to gain a better understanding of tumor biology in the region. (2) Methods: We realize a systematic review of studies on breast cancer in 21 Latin American countries using various databases such as PubMed, Google Scholar, Web of Science, RedAlyc, Dianlet, and Biblioteca Virtual en Salud. Of 392 articles that fit the criteria, 10 studies have clinical data which can be used to create a database containing clinical and genetic information. We compared mutation frequencies across different breast cancer subtypes using statistical analyses and meta-analyses of proportions. Furthermore, we identified overexpressed biological processes and canonical pathways through functional enrichment analysis. (3) Results: 342 mutations were found in six Latin American countries, with the TP53 and PIK3CA genes being the most studied mutations. The most common PIK3CA mutation was H1047R. Functional analysis provided insights into tumor biology and potential therapies. (4) Conclusion: evaluating specific somatic mutations in the Latin American population is crucial for understanding tumor biology and determining appropriate treatment options. Combining targeted therapies may improve clinical outcomes in breast cancer. Moreover, implementing healthy lifestyle strategies in Latin America could enhance therapy effectiveness and clinical outcomes.

show abstract

The MonarchE trial: improving the clinical outcome in HR⁺/HER2⁻ early breast cancer: recent results and next steps

Bertucci

Finetti

Mamessier

et al. 2023

Cancer Communications

View full text Add to dashboard Cite

The MonarchE trial: improving the clinical outcome in HR⁺/HER2⁻ early breast cancer: recent results and next steps

Cited by 4 publications

References 11 publications

Breast cancer in Adolescent & Young Adult (AYA) has a specific biology and poor patient outcome compared to older patients

Breast cancer in Adolescent & Young Adult (AYA) has a specific biology and poor patient outcome compared to older patients

Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis

The MonarchE trial: improving the clinical outcome in HR⁺/HER2⁻ early breast cancer: recent results and next steps

Contact Info

Product

Resources

About

The MonarchE trial: improving the clinical outcome in HR+/HER2− early breast cancer: recent results and next steps

Cited by 4 publications

References 11 publications

Breast cancer in Adolescent &amp; Young Adult (AYA) has a specific biology and poor patient outcome compared to older patients

Breast cancer in Adolescent &amp; Young Adult (AYA) has a specific biology and poor patient outcome compared to older patients

Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis

The MonarchE trial: improving the clinical outcome in HR+/HER2− early breast cancer: recent results and next steps

Contact Info

Product

Resources

About

The MonarchE trial: improving the clinical outcome in HR⁺/HER2⁻ early breast cancer: recent results and next steps

Breast cancer in Adolescent & Young Adult (AYA) has a specific biology and poor patient outcome compared to older patients

Breast cancer in Adolescent & Young Adult (AYA) has a specific biology and poor patient outcome compared to older patients

The MonarchE trial: improving the clinical outcome in HR⁺/HER2⁻ early breast cancer: recent results and next steps